Safety and Tolerability of Glatiramer Acetate (GLACIER)

- Relapsing-Remitting Multiple Sclerosis
- Completed

Study Title: Safety and Tolerability of Glatiramer Acetate

Teva Identifier: GA-MS-303

ClinicalTrials.gov Identifier: NCT01874145

Study Status: Completed

Trial Condition(s): Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: GA 20 mg/mL | Drug: GA 40 mg/mL

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years and older

Trial Duration: 06/01/2013 - 05/01/2014

Phase: Phase 3

Study Type

Interventional